{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T02:14:07Z","timestamp":1781576047224,"version":"3.54.5"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T00:00:00Z","timestamp":1551312000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Rosetrees and Stoneygate Trusts","award":["A1601"],"award-info":[{"award-number":["A1601"]}]},{"name":"Royal Free Charity","award":["0900466"],"award-info":[{"award-number":["0900466"]}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI051355)"],"award-info":[{"award-number":["R01AI051355)"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,19]]},"DOI":"10.1093\/infdis\/jiz089","type":"journal-article","created":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T01:05:48Z","timestamp":1551229548000},"page":"228-232","source":"Crossref","is-referenced-by-count":17,"title":["Original Antigenic Sin Shapes the Immunological Repertoire Evoked by Human Cytomegalovirus Glycoprotein B\/MF59 Vaccine in Seropositive Recipients"],"prefix":"10.1093","volume":"220","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0224-8857","authenticated-orcid":false,"given":"Ilona","family":"Baraniak","sequence":"first","affiliation":[{"name":"Institute for Immunity and Transplantation, University College London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Kern","sequence":"additional","affiliation":[{"name":"Clinical and Experimental Medicine, Brighton and Sussex Medical School, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlo","family":"Holenya","sequence":"additional","affiliation":[{"name":"JPT Peptide Technologies GmbH, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Institute for Immunity and Transplantation, University College London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Reeves","sequence":"additional","affiliation":[{"name":"Institute for Immunity and Transplantation, University College London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,27]]},"reference":[{"key":"2019061902401775500_CIT0001","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/rmv.655","article-title":"Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection","volume":"20","author":"Cannon","year":"2010","journal-title":"Rev Med Virol"},{"key":"2019061902401775500_CIT0002","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.1958","article-title":"Criteria to define interruption of transmission of human cytomegalovirus from organ donor to recipient","volume":"28","author":"Baraniak","year":"2018","journal-title":"Rev Med Virol"},{"key":"2019061902401775500_CIT0003","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/j.1600-6143.2012.04087.x","article-title":"Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy","volume":"12","author":"Atabani","year":"2012","journal-title":"Am J Transplant"},{"key":"2019061902401775500_CIT0004","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.vaccine.2015.11.056","article-title":"Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: a randomized clinical trial","volume":"34","author":"Bernstein","year":"2016","journal-title":"Vaccine"},{"key":"2019061902401775500_CIT0005","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jcv.2009.07.002","article-title":"Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant","volume":"46","author":"Pass","year":"2009","journal-title":"J Clin Virol"},{"key":"2019061902401775500_CIT0006","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial","volume":"377","author":"Griffiths","year":"2011","journal-title":"Lancet"},{"key":"2019061902401775500_CIT0007","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/infdis\/jiy102","article-title":"Epitope-specific humoral responses to human cytomegalovirus glycoprotein-b vaccine with MF59: anti-AD2 levels correlate with protection from viremia","volume":"217","author":"Baraniak","year":"2018","journal-title":"J Infect Dis"},{"key":"2019061902401775500_CIT0008","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.1073\/pnas.1800224115","article-title":"Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies","volume":"115","author":"Baraniak","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Pt 8","key":"2019061902401775500_CIT0009","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1099\/0022-1317-80-8-2183","article-title":"Antigenic domain 1 of human cytomegalovirus glycoprotein B induces a multitude of different antibodies which, when combined, results in incomplete virus neutralization","volume":"80","author":"Speckner","year":"1999","journal-title":"J Gen Virol"},{"key":"2019061902401775500_CIT0010","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.imlet.2007.07.001","article-title":"Location, location, timing: analysis of cytomegalovirus epitopes for neutralizing antibodies","volume":"112","author":"Schrader","year":"2007","journal-title":"Immunol Lett"},{"issue":"Pt 12","key":"2019061902401775500_CIT0011","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1099\/0022-1317-72-12-3017","article-title":"Characterization of a major antigenic region on gp55 of human cytomegalovirus","volume":"72","author":"Silvestri","year":"1991","journal-title":"J Gen Virol"},{"key":"2019061902401775500_CIT0012","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1128\/JVI.65.1.138-146.1991","article-title":"Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus","volume":"65","author":"Kniess","year":"1991","journal-title":"J Virol"},{"key":"2019061902401775500_CIT0013","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1073\/pnas.1800177115","article-title":"HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions","volume":"115","author":"Nelson","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019061902401775500_CIT0014","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1093\/infdis\/jix173","article-title":"The doctrine of original antigenic sin: separating good from evil","volume":"215","author":"Monto","year":"2017","journal-title":"J Infect Dis"},{"key":"2019061902401775500_CIT0015","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/path.4437","article-title":"The pathogenesis of human cytomegalovirus","volume":"235","author":"Griffiths","year":"2015","journal-title":"J Pathol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/220\/2\/228\/28841148\/jiz089.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T17:31:51Z","timestamp":1606584711000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/220\/2\/228\/5366424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,27]]},"references-count":15,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2,27]]},"published-print":{"date-parts":[[2019,6,19]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiz089","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7,15]]},"published":{"date-parts":[[2019,2,27]]}}}